Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

Generated: April 27, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,653,286

« Back to Dashboard

Which drugs does patent 6,653,286 protect, and when does it expire?

Patent 6,653,286 protects GANIRELIX ACETATE and is included in one NDA. There has been one Paragraph IV challenge on Ganirelix Acetate.

This patent has six patent family members in seven countries.

Summary for Patent: 6,653,286

Title: Gonadotropin releasing hormone antagonist
Abstract:The present invention relates to a method to prevent a premature LH surge. The method employs the administration of the gonadotropin releasing hormone antagonist ganirelix in an amount between 0.125-1 mg in combination with exogenous FSH. The method can be used in the treatment of women undergoing controlled ovarian superovulation.
Inventor(s): Mannaerts; Bernadette Maria Julia Louise (Acacialaan, NL), Coelingh Bennink; Herman Jan Tijmen (Melvill van Carnebeelaan, NL), Orlemans; Everardus Otto Maria (Wolvespoor, NL)
Assignee: Akzo Nobel NV (Arnhem, NL)
Application Number:09/446,324
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Organon Usa Inc
ganirelix acetate
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,653,286

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
97201885Jun 20, 1997
PCT Information
PCT FiledJune 16, 1998PCT Application Number:PCT/EP98/03713
PCT Publication Date:December 30, 1998PCT Publication Number: WO98/58657

International Patent Family for Patent: 6,653,286

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia8727798► Subscribe
Germany69831241► Subscribe
Denmark0994718► Subscribe
European Patent Office0994718► Subscribe
Austria302018► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:

Google Plus